Immunotheraphy Punit Dhillon CEO of OncoSec Medical Inc. on Valder Beebe Show-june 24, 2016

Robert H. Pierce, M.D., is the Chief Scientific Strategist at Oncosec. He is listed under the Who We Are/Management tab on the Oncosec website. He is still very much a part of the Oncosec Team.
Good luck shareholders. Next friday should reveal promising data at SITC.

This is a good sign that Lung Cancer may be the next indication that they will target. I like it!
Dr. Pierce is in it to win it.

That would be a serious market to go after. I hope that is their intention.

Oncosec Facebook entry today about Lung Cancer awareness. Hmm. Hint, hint, maybe?
Next week should be exciting build up to data release friday. Good luck shareholders.

If toxicity levels were to become an ongoing problem with Opdivo and also Keytruda, maybe Merck would be interested in a trial involving EP-IL12 +Keytruda in Responders as well as non-responders but at lower dosages of Keytruda.

Big market opportunity for Oncosec about to open up. Merck and Roche have the deep pockets we need. If they are smart they won't wait to partner with Oncosec. Maybe Japanese interest the likes of Daiichi Sankyo or Takeda will jump in on this also after data is released. Multiple partnerships would not be out of the question.

ONCOSEC HAS BEEN A DIAMOND IN THE ROUGH FOR A FEW YEARS NOW. THAT IS ABOUT TO CHANGE FOR THE BETTER THOUGH. FOCUS ON THE SCIENTIFIC FACTS AND DATA. SOUND INVESTMENT HERE! GOOD LUCK TO ALL INVESTORS IN ONCOSEC. LOOKING FORWARD TO GAME-CHANGING DATA ON NOVEMBER 11TH AND NOVEMBER 17TH.

ONCOSEC IS VERY ACTIVE ON THEIR FACEBOOK PAGE LATELY WITH UPDATES. TODAY THEY POSTED A PROMOTION FOR THE SITC ORAL PRESENTATION. THEY SOUND VERY POSITIVE. NEWS WILL BE GOOD. BANK ON IT!

I like that we are presenting at Stifel Nicolaus Weisel Healthcare Conference 2 days before our Analyst and Investor day. Good opportunity to move up in the analyst ranks. Nice string of events to optimize exposure. Nice!

Dirk, I posted a list from Oncosec's website about a month ago. The events they listed were apparently
events "the Oncosec Scientific Team" would be attending, but not necessarily presenting at. Now we know that the Stifel Conference is one they will be presenting at and it was on the presenting list of events last month. In any case the most important thing we know is that the news we need to hear is coming on Nov. 11th and Nov. 17th. They did have 13 events listed but maybe these were just possible events to release the data that will come at SITC. When the late-breaking abstract acceptance at SITC came, there is no need now to worry about which event they will release the data at. We are moving forward that is the key.

Oncosec stock on the move up. No doubt about that! Good news coming Nov. 11th and Nov. 17th.
Happy Halloween all! Hoping for treats and no tricks in November!

Update to Clinical Pipeline-

(Metastatic Melanoma trial)-

Phase II study to assess the safety and efficacy of multiple treatment cycles of ImmunoPulse® IL-12 monotherapy in patients with in-transit cutaneous and subcutaneous metastatic melanoma. Patients are currently being enrolled into an extension arm of the study to evaluate a new six-week treatment cycle.

Apparently Oncosec is not abandoning the EP-IL12 as a monotherapy.

BARCHART.COM REGISTERING A 100% BUY ON ONCOSEC!

http://www.barchart.com/opinions/stocks/ONCS

I view this as responsible management looking after the employees who help to bring the breakthrough science to fruition.....a clear sign of good trustworthy management.

Think Automatic Vesting on a Change in Control Is Not Important?

http://www.winston.com/en/executive-compensation-blog/think-automatic-vesting-on-a-change-in-control-isn-t-important.html

This article is about a court case involving an employee who did not have vested stock options and lost her stock options when the company she worked for was sold, even though she continued to do the same job with the new company owners.

THIS IS WHAT COULD HAPPEN TO ONCOSEC EMPLOYEES IF MANAGEMENT DID NOT MAKE THIS AMENDMENT.

This could also be another reason why Dr. Pierce changed roles to consultant.


To all serious investors and believers in Oncosec; do not be discouraged by negative posters.
We have heard it before but we are really at a major inflection point here and management is going to be in full force to capitalize on it.


SITC followed by the investor day is just the start here.

RECENT PROXY STATEMENT WORDING SHOULD NOT BE UNDERESTIMATED...IT IS VERY IMPORTANT AND REPRESENTS VERY BULLISH SENTIMENT BY ONCOSEC MANAGEMENT.
IT PROTECTS EMPLOYEES STOCK OPTIONS IN THE EVENT ONCOSEC AGREES TO A COMPANY BUYOUT.


PROPOSAL 2

Automatic Vesting Upon a Change in Control

The Existing Plan provides that the Plan Administrator may, but is not required to, provide for the full or partial automatic vesting and exercisabilityof one or more outstanding unvested awards under the Existing Plan and the release from restrictions on transfer and repurchase or forfeiture rights of such awards in connection with a corporate transaction or change in control. In addition, the Plan Administrator may, but is not required to, condition any such award vesting and exercisability or release from such limitations upon the subsequent termination of the continuous service of the grantee within a specified period following the effective date of the corporate transaction or change in control, and may provide that any awards so vested or released from such limitations in connection with a change in control shall remain fully exercisable until the expiration or sooner termination of the award.

The Amended Plan would provide for the automatic vesting and exercisability, and the lapsing of all other conditions applicable to vesting and exercisability, of all unvested of all awards under the Amended Plan upon a change in control of the Company, with no action required on the part of the Plan Administrator. Any performance criteria relevant to such awards shall be deemed to have been achieved at the target performance level. The Plan Administrator may provide that awards that remain outstanding after vesting will be assumed or replaced in connection with the change in control. The Plan Administrator may also provide for the cashing out of outstanding and vested options and stock appreciation rights based on the based upon the per-share consideration being paid in connection with such change in control, less the applicable exercise price or base amount. The Amended Plan also modifies the definitions of “Change in Control” and “Corporate Transactions.”

LIST OF UPCOMING EVENTS ONCOSEC WILL BE ATTENDING. We should get a PR soon letting us know which events they are presenting at. At the very least there are a lot of events that Oncosec will be networking at. November and December should se some excitement for sure.

World Cancer Congress
October 31 – November 3, 2016 | Paris, France

BIOSafe Meetings
November 2-3, 2016 | Basel, Switzerland
ESMO Immuno-Oncology
November 4-6, 2016 | Lausanne, Switzerland
Society for Melanoma Research (SMR)
November 6-9, 2016 | Boston, MA
Credit Suisse Healthcare Conference
November 7-9, 2016 | Phoenix, AZ
World Pharma Congress
November 7-9, 2016 | Las Vegas, NV
Society for Immunotherapy of Cancer (SITC)
November 9-13, 2016 | National Harbor, MD
American Association of Pharmaceutical Scientists (AAPS) Annual Meeting
November 13-17, 2016 | Denver, CO
Annual NeoAntigen Summit
November 14-17, 2016 | Boston, MA
Stifel Nicolaus Weisel Healthcare Conference 2016
November 15-16, 2016 | New York City, NY
Inaugural Cancer Immunotherapy Summit
November 21-22, 2016 | Berlin, Germany
International Conference on Translational Medicine
November 28-30, 2016 | San Francisco, CA
International Conference on Translational Medicine
November 28-30, 2016 | San Francisco, CA
Piper Jaffray Annual Healthcare Conference
November 29-30, 2016 | New York City, NY
EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
November 29 – December 2,2016 | Munich, Germany

International Conference and Exhibition on Immunology
December 1-2, 2016 | Chicago, IL
World Congress on Cancer Therapy
December 5-7,2016 | Philadelphia, PA
LD Micro Conference
December 6-8, 2016 | Los Angeles, CA
San Antonio Breast Cancer Symposium (SABCS)
December 6-10, 2016 | San Antonio, TX

Yes, we should be getting a PR for November events. Remember on Oncosec's website they had listed around 13 events before I e-mailed them to get some clarity about which events they are presenting at and the events they are attending. So they could be presenting at any one of those 13 events. We will see. They are not listed on the website anymore so I would have to go back to my previous posts to find the list.

Weak hands being shaken out now. Hold on to your shares if you are a smart investor. Next week this will head higher.

Yes, technically we are in great shape for a rebound back up here. Lets hope we keep the momentum going followed by great news in November! GO ONCOSEC LONG!

Same here. About time we had a good run here for all the long holders.

Above average volume in first 20 minutes.....very good sign the buying continues in anticipation of Nov. 11th.

Oncosec may also have really impressed a few investors at the Sofinnova Japan Conference.

Proxy Statement release today may be the reason for the stock price move:

This looks like an ammendment to stock options in the event of a company takeover.

Automatic Vesting Upon a Change in Control

The Existing Plan provides that the Plan Administrator may, but is not required to, provide for the full or partial automatic vesting and exercisability of one or more outstanding unvested awards under the Existing Plan and the release from restrictions on transfer and repurchase or forfeiture rights of such awards in connection with a corporate transaction or change in control. In addition, the Plan Administrator may, but is not required to, condition any such award vesting and exercisability or release from such limitations upon the subsequent termination of the continuous service of the grantee within a specified period following the effective date of the corporate transaction or change in control, and may provide that any awards so vested or released from such limitations in connection with a change in control shall remain fully exercisable until the expiration or sooner termination of the award.

The Amended Plan would provide for the automatic vesting and exercisability, and the lapsing of all other conditions applicable to vesting and exercisability, of all unvested of all awards under the Amended Plan upon a change in control of the Company, with no action required on the part of the Plan Administrator. Any performance criteria relevant to such awards shall be deemed to have been achieved at the target performance level. The Plan Administrator may provide that awards that remain outstanding after vesting will be assumed or replaced in connection with the change in control. The Plan Administrator may also provide for the cashing out of outstanding and vested options and stock appreciation rights based on the based upon the per-share consideration being paid in connection with such change in control, less the applicable exercise price or base amount. The Amended Plan also modifies the definitions of “Change in Control” and “Corporate Transactions.”

Can we hit 1 million share volume today?

Bingo! Time for the Market to wake up to this. Long time coming.

Volume continues to move up now. Up triple in last 10 minutes....something brewing for sure.

How Immune Checkpoint Inhibitors work video tweeted by Punit:

Volume just doubled, now we are getting somewhere. Investors starting to move in.

I remember reading this article. Very positive. The science is moving forward and that is the most important thing we have to remember. Nobody has an exact timeline. It will be all good though in time.

This shows further validation of the growing use of biomarker assays to screen and enroll patients in trials that they are more likely to respond to. Oncosec's combo trial with Merck is the first Melanoma trial in phase II study to screen patients using a biomarker assay.

Using the biomarker assay the patients enrolled in Oncosec's combination trial with Keytruda are most likely to not respond to Keytruda monotherapy. That is the consensus and that is very much keeping it real according to scientific data.

What is the mixup here? Oncosec is screening patients with a biomarker assay and intentionally enrolling patients who are unlikely to respond to Keytruda monotherapy in their combination trial. This is the first combination trial to do this and why interim data coming up next month is so important.

Merck sales of Keytruda are just getting started. Sales of Keytruda are expected to hit $3 Billion in 2017. That is a 100% growth rate in the next year. That will double again by 2020 to roughly $6 Billion. Logically what would the next best road to travel be for expansion of Keytruda and pump those sales up beyond belief?.....Addressing the 70% of patients that do not respond to Keytruda monotherapy. Big market opportunity here for Oncosec. Right place, right time. You never know, Merck might open up that wallet after Nov. 11th to lock this down. Hoping. Go Oncosec!

Strange Broker update on Scottrade today. This did pop up today even though it is obviously outdated.

News Update on Oncosec:

OncoSec Medical Maintained With a $25.00/Share Price Target by H.C. Wainwright
3 hours 57 minutes ago - DJNF
Ratings actions from Benzinga: http://www.benzinga.com/stock/ONCS/ratings

(END) Dow Jones Newswires

October 26, 2016 15:51 ET (19:51 GMT)


I would love to see old target prices reinstated.....maybe after Nov. 11th?

I would say it is a very positive sign having an investor day right after a significant data release at a scientific conference. The results are under embargo because it is a "late-breaking abstract" so I believe announcing an investor day is a smart legal way of saying they are going to announce positive results without actually saying it before SITC. Announcing the investor day weeks ahead of time will hopefully ensure they have a lot of interested Investors tuning in to the webcast. I think this will be a webcast investor day event only.

Seriously hope so. Good luck to us all here!

I don't see your point. This is old news. They paid for a service that they are not specialized to do themselves.

I agree with you Titan. We just need to hold tight. Good news will mean we get a lot more Institutional interest as well as partnership interest in Oncosec. Punit has been very active on twitter. He seems very positive with the impending news to be released next month as well as the investor day.